(PR1E) Amundi Index Solutions - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: LU1931974262

PR1E: Large-Cap Equity, Blend Equity

Amundi Index Solutions - Amundi Prime Europe UCITS ETF DR (XETRA:PR1E) is an exchange-traded fund that tracks the Morningstar Developed Markets Europe TME NR EUR Index, providing investors with broad exposure to large-cap European equities. The fund is domiciled in Germany and is designed to deliver a blend of European stocks, making it a diversified investment option for those seeking to tap into the European market.

The ETFs investment strategy is centered around replicating the performance of its underlying index, which comprises a selection of European stocks from developed markets. By doing so, it offers investors a low-cost and efficient means of accessing the European equity market. The funds assets under management (AUM) stand at €85.54 million, indicating a moderate level of investor interest.

From a technical analysis perspective, the ETFs price action suggests a bullish trend, with the short-term Simple Moving Average (SMA20) and medium-term Simple Moving Average (SMA50) indicating a positive momentum. The Average True Range (ATR) is relatively low at 1.74%, suggesting that the ETFs price is not experiencing significant volatility. Given the current price of €31.13, the SMA20 at €29.95, and the SMA50 at €29.87, it is likely that the ETF will continue to move upwards, potentially testing the 52-week high of €31.77.

Combining technical and fundamental analysis, a forecast for Amundi Prime Europe UCITS ETF DR can be derived. With the ETFs underlying index tracking the European equity market, and considering the current economic environment, it is likely that the fund will continue to benefit from a positive trend in European stocks. Assuming the AUM continues to grow, and the ETFs tracking error remains minimal, the price is forecasted to reach €32.50 in the short term, representing a potential upside of 4.4% from current levels. However, investors should be cautious of potential risks, including market downturns and changes in investor sentiment.

Additional Sources for PR1E ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PR1E ETF Overview

Market Cap in USD 100m
Category Europe Large-Cap Blend Equity
TER 0.05%
IPO / Inception 2019-01-30

PR1E ETF Ratings

Growth Rating 71.3
Fundamental -
Dividend Rating 67.9
Rel. Strength -7.41
Analysts -
Fair Price Momentum 30.67 EUR
Fair Price DCF -

PR1E Dividends

Dividend Yield 12m 2.71%
Yield on Cost 5y 4.48%
Annual Growth 5y 11.03%
Payout Consistency 95.9%
Payout Ratio %

PR1E Growth Ratios

Growth Correlation 3m 70.1%
Growth Correlation 12m 64.7%
Growth Correlation 5y 91.2%
CAGR 5y 11.05%
CAGR/Max DD 5y 0.56
Sharpe Ratio 12m 0.85
Alpha -2.24
Beta 0.515
Volatility 13.31%
Current Volume 2.1k
Average Volume 20d 1.7k
What is the price of PR1E shares?
As of July 01, 2025, the stock is trading at EUR 30.80 with a total of 2,145 shares traded.
Over the past week, the price has changed by +1.20%, over one month by -1.64%, over three months by +2.58% and over the past year by +7.54%.
Is Amundi Index Solutions a good stock to buy?
Yes. Based on ValueRay´s Analyses, Amundi Index Solutions (XETRA:PR1E) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 71.26 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PR1E is around 30.67 EUR . This means that PR1E is currently overvalued and has a potential downside of -0.42%.
Is PR1E a buy, sell or hold?
Amundi Index Solutions has no consensus analysts rating.
What are the forecasts for PR1E share price target?
According to our own proprietary Forecast Model, PR1E Amundi Index Solutions will be worth about 34.5 in July 2026. The stock is currently trading at 30.80. This means that the stock has a potential upside of +12.05%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 34.5 12%